Skip to main content
Clinical Trials/NCT00237874
NCT00237874
Completed
Phase 2

Aripiprazole Treatment of Prodromal Patients

Yale University2 sites in 1 country15 target enrollmentFebruary 2004

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Schizophrenia
Sponsor
Yale University
Enrollment
15
Locations
2
Primary Endpoint
Total Score of the Scale Of Prodromal Symptoms
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

We hypothesize that symptoms will improve in patients who meet diagnostic criteria for the schizophrenia prodrome when they are prescribed aripiprazole.

Detailed Description

This is an 8 week trial with extension for responders out to one year. All patients receive active medication; there is no placebo. Patients must meet criteria for the schizophrenia prodrome according to the Structured Interview for Prodromal Syndromes. Patients receive counseling as well. All counseling and medication are free of charge.

Registry
clinicaltrials.gov
Start Date
February 2004
End Date
February 2007
Last Updated
11 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • age 13 to 40 meet criteria for the prodrome for schizophrenia

Exclusion Criteria

  • history of psychosis

Outcomes

Primary Outcomes

Total Score of the Scale Of Prodromal Symptoms

Time Frame: 8 weeks

This is a 19-item scale with items scores 0-6. Treatment response is defined as all 5 Scale of Prodromal Syndromes positive symtpom items being rate below the prodromal range (\< or equal to 2).

Study Sites (2)

Loading locations...

Similar Trials